Revotar’s focus is on the discovery (rational drug design) and development of small molecule anti-inflammatory drug candidates for respiratory indications such as chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI).
 
Our main target for rational drug design is the selectin family of cell adhesion molecules, comprised of three structurally related calcium-dependent carbohydrate binding proteins, E-, P- and L-selectin. The selectins mediate the initial rolling or "tethering" of leukocytes on the vascular endothelium following inflammation or injury which leads to migration of inflammatory cells from the circulation into the surrounding tissue.

This process is generally considered to be a key relevant event in the inflammatory response and thus constitutes a target for therapeutic intervention in the modulation of inflammation. Presently, different types of selectin antagonists are under development including Bimosiamose, which is the most advanced molecule in development (see product pipeline).